Cellares and BMS Extend Collaboration to Include a Second CAR-T Asset; Kristin Yarema Appointed as Poseida’s CEO Replacing Mark Gergen

On October 10, Cellares announced an extension of its agreement with BMS to include a second CAR-T Program in Cellares’s Technology Adoption Partnership (TAP) Program (press release). A day earlier, Poseida reported a leadership transition with Kristin Yarema appointed as the new CEO expected to be effective January 1, 2024, while Mark Genger, current CEO, will transition to Executive Chairman of the company (press release). Below, Celltelligence provides insights about the expanded Cellares-BMS collaboration and speculates about which of BMS’s preclinical assets could have been partnered.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.